TPTE2

Across TCGA pan-cancer cohorts, TPTE2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TPTE2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TPTE2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TPTE2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

HNSC, UCEC, and BLCA are the cancer types where TPTE2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.141	0.673	<.001	36	view →
UCEC	DFS	Median	All	0.980	0.823	.003	32	view →
BLCA	OS	Median	All	0.173	0.692	.001	15	view →
LUSC	DFS	Median	All	0.758	0.378	.004	12	view →
CESC	DFS	Median	III,IV	0.240	0.726	.015	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
COAD	OS	Median	All	0.611	0.874	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TPTE2–HNSC (OS)

Open the HNSC breakdown →